Research reference
Purity and identity are the two pillars of peptide batch release. High-performance liquid chromatography (HPLC) and mass spectrometry (MS) are the standard analytical pairing used to verify both before material is approved for dispatch to research laboratories.
In peptide supply, purity is almost always reported as area percent on an HPLC chromatogram: the integrated area of the main peptide peak divided by the total integrated area of all detected peaks, multiplied by 100. A result of ≥99% indicates that deletion sequences, truncated analogues, and other synthesis-related impurities together account for less than 1% of detected material under the stated chromatographic method.
This is a relative measure — it depends on the column, gradient, and detection wavelength used. Reputable suppliers document the method or reference a standard operating procedure on the CoA.
Reverse-phase HPLC separates peptides by hydrophobicity. Shorter deletion sequences typically elute earlier or later than the full-length product, appearing as distinct peaks. Common impurities include:
HPLC confirms purity but cannot alone confirm that the main peak is the intended sequence — that requires mass spectrometry.
MS measures the mass-to-charge ratio (m/z) of ionised peptide molecules. For a synthetic peptide, the observed molecular ion (or multiply charged envelope) should match the calculated monoisotopic or average mass of the target sequence, accounting for counter-ions such as trifluoroacetate (TFA) from purification.
Together, HPLC purity and MS identity provide a defensible batch release package for research use. Optimus Peptides specifies ≥99% purity on every catalogue peptide, with batch CoA available on request.
When comparing suppliers, look beyond a headline purity figure: